Acute Management of Wasting Syndrome (Cachexia)

PH284 is an odorless, tasteless synthetic investigational pherine nasal spray with a novel, rapid-onset potential mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments for the loss of appetite associated with chronic disorders such as cancer. Cachexia is a serious but under-recognized consequence of many chronic diseases with body mass loss of >10% and a prevalence of 5 to 15 %. Vistagen believes PH284 may have therapeutic potential for improving subjective feelings of hunger in patients with cachexia.

Vistagen is currently evaluating the path forward for PH284, including assessing studies Vistagen believes will be necessary to submit a U.S. IND for further Phase 2 clinical development of PH284, on its own or with collaborators, as well as evaluating the appropriate patient populations for demonstrating an increase in appetite and weight gain.

For more information on partnering with Vistagen, please contact us at bd@vistagen.com.